테네시의 유방암 임상 시험
유방암 관련 연구 91개가 테네시 내 여러 지역에서 참여자를 모집하고 있습니다.
테네시의 도시
공식 연구 텍스트(영어)
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- The West Cancer Center, Memphis
- SCRI Oncology Partners, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT07701941Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Sarah Cannon Research Institute, Nashville
피험자 모집 중3상
18세 ~ 100세 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT05827081A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Sarah Cannon Research Institute (Nashville), Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT07102381A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Tennessee Oncology, Greco-Hainsworth Center for Research, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06369285Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06625775A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06172478Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Baptist Cancer Center - Memphis, Memphis
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Pllc, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT06324357A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT05877599IKS014 in Advanced Solid Tumors That Express HER2
- Tennessee Oncology, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05872295A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0068), Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07060807BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Scri Oncology Partners, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06120283A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Chattanooga
- Research Site, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06103864A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Tennessee Cancer Specialists ( Site 7001), Knoxville
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06966700The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Baptist Memorial Healthcare, Memphis
피험자 모집 중3상
60세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06377852A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
- West Cancer Center, Germantown
피험자 모집 중2상
18세 이상 · 여성 · 2026. 9. 25. 업데이트됨 · NCT07054190Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- Vanderbilt Ingram Cancer Center, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT05523947Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Bartlett
- Clinical Trial Site, Knoxville
- Clinical Trial Site, Mount Juliet
- 외 2개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- West Cancer Center, Germantown
- Vanderbilt, Nashville
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT07214532A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Tennessee Medical Center, Knoxville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT06618287A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Sarah Cannon Research Institute SCRI, Nashville
- Nashville General Hospital, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Tennessee Oncology, Nashville
피험자 모집 중2상
18세 이상 · 여성 · 2026. 9. 22. 업데이트됨 · NCT07287098A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- SCRI Oncology Partners, Nashville
피험자 모집 중1상
18세 이상 · 여성 · 2026. 9. 21. 업데이트됨 · NCT07524855A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Sarah Cannon Nashville, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07109726A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- SCRI Oncology Partners, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT06827236ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- The West Clinic, P.C. dba West Cancer Center, Germantown
- Tennessee Oncology, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07173751The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT04585750A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Baptist Cancer Center, Memphis
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT06492616Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- SCRI Oncology Partners ( Site 7000), Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT06797635A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Tennessee Oncology - Chattanooga Oncology & Hematology Associates, Chattanooga
- The West Clinic, Germantown
- Tennessee Oncology PLLC, Nashville
- 외 1개
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT03424005Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT06253871Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
- The West Clinic, PC dba West Cancer Center, Germantown
피험자 모집 중
70세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT07629206Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- SCRI Oncology Partners, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT05386108A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Center, Nashville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT06440005A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT07100106A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Nashville
피험자 모집 중3상
18세 ~ 130세 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT07647328Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Institute, Nashville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07287917A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- West Cancer Center, Germantown
- Vanderbilt University Medical Center, Nashville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT06790693Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Nashville General, Nashville
피험자 모집 중관찰 연구
18세 ~ 99세 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07211178A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT06760819ClinicalTrials.gov 출처, 2026. 10. 2. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.